News
23andMe (and Your Genetic Data) Sold to Regeneron in Bankruptcy Auction
Genetic testing company 23andMe isn’t going away, despite declaring bankruptcy. The company and nearly all of its assets, including its biobank of customer genetic samples, have been purchased by American biotechnology company Regeneron Pharmaceuticals for a cool $256 million, the highest bid submitted in the once-hot startup’s bankruptcy auction.
Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Monday that it has secured the winning bid in the bankruptcy auction for key assets of 23andMe Holding Co. in a $256 million deal to boost its genetics-based drug discovery efforts.
Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...
The company has signed up to pay $256 million for 23andMe and nearly all of its assets, including its R&D services operations ...
How exactly 23andMe will shake out after the Regeneron purchase is to be seen. The company has taken a dramatic fall in ...
Multiple bidders are likely to submit offers for the DNA data bank and other assets of bankrupt genetic-testing firm 23andMe ... receive multiple competitive bids by tomorrow’s deadline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback